This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Media
-
Cancer Drug Trial
Race Oncology CSO Dr Daniel Tillett talks to WIN Television News about Race Oncology’s research collaboration with the University of Wollongong.
-
Race Receives Human Ethics Approval for Extramedullary AML & MDS Trial
6 April 2022 – Race Oncology Limited (“Race”) is pleased to announce it has receivedhuman ethics approval for its open label clinical trial of Zantrene® (bisantrenedihydrochloride) in patients with extramedullary Acute Myeloid Leukaemia (AML) or highrisk Myelodysplastic Syndrome (MDS). Before patients can be enrolled and treated at the lead site – Calvary Mater NewcastleHospital –…